Evidence map›Paper›PMID 42134594›Full record

ReviewTransplantation and cellular therapy2026

Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy.

Olalekan O Oluwole, Leslie Crofford, Andrew P Jallouk, Daniel W Lee, Rebecca Gardner, Amanda L Piquet, Shaun W Jackson, Alejandro Marinos Velarde, Everett Meyer, Tristan E Knight and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Olalekan O OluwoleDivision of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: olalekan.oluwole@VUMC.org.
Leslie CroffordDivision of Rheumatology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Andrew P JalloukDivision of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Daniel W LeeDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, Virginia.
Rebecca GardnerDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Amanda L PiquetDepartment of Neurology, University of Colorado Anschutz, Aurora, Colorado.
Shaun W JacksonCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington; Department of Pediatrics, University of Washington School of Medicine; Seattle, Washington.
Alejandro Marinos VelardeDivision of Hematology and oncology, Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.
Everett MeyerDepartment: Medicine, Blood, and Marrow Transplantation, Stanford University, Stanford, California.
Tristan E KnightDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Hawaii, Honolulu, Hawaii.
Madhav R SeshadriDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Sayeef MirzaDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Kara WackerFoundation for the Accreditation of Cellular Therapy, Omaha, Nebraska.
Erin WilfongDivision of Rheumatology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

Immunophenotypes in the Idiopathic Inflammatory MyopathiesK08AR080808 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Erin M Wilfong · 2022 to 2026
$818k
NIAMS NIH HHS K08 AR080808
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a standard of care in many lymphoid malignancies and has emerged as potentially curative. A unique property of this one-time treatment is profound and long-lasting B cell depletion, hence the quest to explore its impact in the treatment of severe autoimmune disorders. Early trials in select populations have shown preliminary benefit. However, many questions persist as to how best to deploy this potentially highly effective therapy in the treatment of autoimmune disorders. The American Society for Transplantation and Cellular Therapy Committee on Cellular Therapy convened a group of experts in hematology, oncology, and autoimmunity to provide in a question and answer format a review of the existing publications on CAR-T cell therapy in autoimmune disorders including subtypes, discuss types of clinical trials, strategies to optimize patient safety, monitoring and toxicity management, tracking organ dysfunction in different types of autoimmune disorders, and financial considerations with the goal of providing a guide to physicians who want to be involved in CAR-T cell therapy in autoimmune disorders.

Indexed as

Autoimmune DiseasesCell- and Tissue-Based TherapyImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansSocieties, MedicalUnited StatesReceptors, Chimeric AntigenAdultsAutoimmune disorderCellular therapyChimeric antigen receptor (CAR) T cellsCRSICANSPediatrics

Identifiers

PMID42134594
PMCPMC13656796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.